See Why the Alaska Permanent Fund is Smiling
The Alaska Permanent Fund Corporation (APFC) took a calculated risk and bought in early in Seattle-based Juno Therapeutics. Financially backing pharmaceutical firms in the early-stage process is risky. The wealth fund rode its investment in Juno Therapeutics far beyond the pharmaceutical company’s initial public offering (IPO). On the morning of June 30th, Juno Therapeutics’ shares went up more than 33% in pre-market trading.
[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]
Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute